- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
Health professional alleged Roche employees’ LinkedIn ‘Experience’ sections promoted POMs without mandatory info. Panel and Appeal Board found the content was CV-style,…
Complaint alleged Shingrix promotion on an employee’s personal LinkedIn post/profile. Panel found no promotion to the public or HCPs and ruled no…
Novo Nordisk emailed HCPs about GLP-1RA supply during Lilly’s Trulicity dose outage. Panel found the wording implied Lilly didn’t prioritise supply, breaching…
Complaint alleged an email invite promoted Mayzent outside its licence, was uncertified, and didn’t clearly restrict access to HCPs. PMCPA ruled no…
PMCPA found Roche’s Rozlytrek dosing webpage misleading because it omitted key SPC dose-modification/discontinuation guidance for several safety scenarios in a black triangle…
BMJ print ad implied contraceptive pills were licensed to help skin issues, “balance hormones” and manage cycles, without qualification. Panel also found…
A supplier payment-terms letter sent to 266 UK vendors included promotional language about three medicines and an asset in development. It was…
A US-facing LinkedIn post about an FDA-approved lung cancer combo was liked/commented on by 14 UK-based AstraZeneca employees, triggering ABPI Code breaches…
A senior UK-based GSK medical employee ‘loved’ an external LinkedIn post about rectal cancer immunotherapy. Panel said this likely disseminated off-label promotion…
Ex-employee alleged an individual promoted medicines to HCPs for 2+ years without ABPI qualification. Panel found no evidence for the 2-year claim…
At ECCMID 2022, a UK HCP presentation was ruled promotional for Spikevax and included booster-dose data inconsistent with the SPC. Breaches: Clauses…
Complaint alleged a senior AstraZeneca leader’s LinkedIn ‘About’ section promoted POMs to the public and referenced unlicensed indications/trials. Panel ruled no breach…
Ipsen admitted an employee in a promotional role in Northern Ireland had no verified ABPI representative exam on file. PMCPA ruled breaches…
PMCPA ruled GSK’s EAMS press release for dostarlimab was promotional, sent to mainstream media, and promoted an unlicensed indication. Breaches: 5.1, 11.2,…
PMCPA ruled AstraZeneca’s Tagrisso Connect HCP site breached the Code because the first promotional pop-up lacked prescribing information and didn’t clearly signpost…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.